Patent US4702909A successfully refreshed from Google Patents.
US4702909A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Non-A, non-B hepatitis antigen, antigen compositions, vaccine and diagnostic reagent
Assignee: Louisiana State University
•
Filing: 1984-04-26
•
Granted: 1987-10-27
•
Expires: 2004-04-26
Abstract
Abstract Non-A, non-B hepatitis antigen, antigen compositions, vaccine and assay test for the detection of non-A, non-B hepatitis antigen. The antigen is characterized as having a particle size of about 2.0 nm to about 5.0 nm, a density of from about 1.24 to about 1.30 g/cm 3 , contains ribonucleic acid and occurs either free or bound to IgG molecules. The antigen can be isolated by isopycnic banding and chromatographic fractionation, and preferably by enzymatic digestion, isopycnic banding and chromatographic fractionation.
Inventors
- 👤 Victor M. Villarejos
- 👤 Kirsten A. Visona
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 09:32
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/29; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/576; G01N33/5767; A61K2039/51; A61K2039/525; A61K2039/5252; A61K2039/555; A61K2039/55505; C; C12; C12N; C12N2770/00; C12N2770/00011; C12N2770/24011; C12N2770/24211; C12N2770/24234; Y; Y10; Y10S; Y10S436/00; Y10S436/82
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
36 words
A substantially purified non-A, non-B hepatitis antigen ATCC 40322, consisting essentially of particles having a size from about 2.0 to about 5.0 nm, and a density of from about 1.24 to about 1.30 g/cc in CsCl.
Claim 2
Dependent Claim
36 words
A substantially purified non-A, non-B hepatitis antigen ATCC 40322, consisting essentially of particles having a size from about 2.0 to about 5.0 nm, and a density of from about 1.24 to about 1.30 g/cc in CsCl.
Claim 3
Dependent Claim
19 words
The antigen according to claim 1 having a molecular weight of from about 200,000 daltons to about 300,000 daltons.
Claim 4
Dependent Claim
34 words
The antigen according to claim 1 which, when complexed with human lipoproteins of host origin , or human, immunoglobin G. has a molecular weight of from about 800,000 daltons to about 1,000,000 ol daltons.
Claim 5
Dependent Claim
21 words
A subunit antigenic component of the non-A, non-B hepatitis antigen of claim 1 having a molecular weight of about 50,000 daltons.
Claim 6
Dependent Claim
12 words
A composition comprising the antigen of claim 1 in an aqueous vehicle.
Claim 7
Dependent Claim
16 words
A composition according to claim 5 wherein the vehicle is water, saline or phosphate buffered saline.
Claim 8
Dependent Claim
9 words
The antigen according to claim 1 adsorbed on alum.
Claim 9
Dependent Claim
18 words
A vaccine comprising an immunologically effective amount of the antigen of claim 1 and a physiologically acceptable vehicle.
Claim 10
Dependent Claim
33 words
The antigen according to claim 1 further defined in that the sedimentation coefficient of the particles ranges from about 30 S to about 40 S (linear sucrose gradient), and it contains ribonucleic acid.
Claim 11
Dependent Claim
26 words
A diagnostic reagent comprising the antigen of claim 1 in an aqueous medium in a quantity effective to form an immune complex in a diagnostic assay.
Claim 12
Dependent Claim
54 words
A process for isolating a non-A, non-B hepatitis antigen ATCC 40322 , subjecting serum containing non-A, non-B hepatitis antigen, ATCC 40322, to isopycnic banding and selecting a fraction having a density equivalent to from about 1.24 to about 1.30 g/cc in CsC1, and a particle size of from about 2.0 to about 5.0 nm.
Claim 13
Dependent Claim
54 words
A process for isolating a non-A, non-B hepatitis antigen ATCC 40322 , subjecting serum containing non-A, non-B hepatitis antigen, ATCC 40322, to isopycnic banding and selecting a fraction having a density equivalent to from about 1.24 to about 1.30 g/cc in CsC1, and a particle size of from about 2.0 to about 5.0 nm.
Claim 14
Dependent Claim
27 words
A process according to claim 11 wherein the selected fraction is treated to separate particles having a molecular weight of from about 200,000 to about 300,000 daltons.
Claim 15
Dependent Claim
42 words
A process according to claim 11 wherein the selected fraction is treated to separate particles which, when complexed with human lipoproteins of host origin, or human immunoglobin G, have has a molecular weight of from about 800,000 daltons to about 1,000,000 daltons.
Claim 16
Dependent Claim
37 words
A process according to claim 11 wherein the treatment separates particles having a molecular weight of from about 200,000 to about 300,000 daltons, and particles having a molecular weight of from about 800,000 to about 1,000,000 daltons.
Claim 17
Dependent Claim
36 words
The process according to claim 11 wherein the antigen is further defined in that the sedimentation coefficient of the particles ranges from about 30 S to about 40 S (linear sucrose gradient), and contains ribonucleic acid.
References Cited (Backward Citations)
JPS55122156A
Cited
US4395395A
Cited
US4291020A
Cited
WO1982000205A1
Cited
US4464474A
Cited
EP0061974A2
Cited
US4542016A
Cited
JPS57175127A
Cited
EP0093430A2
Cited
WO1983004371A1
Cited
US4511556A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-10-26 | 1991-04-27 | 1991-10-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-10-26 | 1995-04-27 | 1995-10-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-10-26 | 1999-04-27 | 1999-10-27 | $7700.00 | Window Closed / Lapsed |